确认对外授权一次性收入，恒瑞医药上半年业绩大幅增长

蓝鲸财经08-22 19:15

蓝鲸新闻8月22日讯（记者屠俊）8月21日晚，江苏恒瑞医药股份有限公司（恒瑞医药，600276.SH）发布2024年半年报，上半年营业收入136.01亿元，同比增长21.78%；归母净利润34.32亿元，同比增长48.67%；归母扣非净利润34.90亿元，同比增长92.94%，环比增长50.69%。值得注意的是，半年报中指出，恒瑞医药已将收到的Merck Healthcare 1.6 亿欧元（...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2461909653?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-22 19:15","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2461909653","market":"sh","top_or_hot":-1,"title":"确认对外授权一次性收入，恒瑞医药上半年业绩大幅增长","media":"蓝鲸财经","content":"<div>\n<p>蓝鲸新闻8月22日讯（记者 屠俊）8月21日晚，江苏恒瑞医药股份有限公司（恒瑞医药，600276.SH）发布2024年半年报，上半年营业收入136.01亿元，同比增长21.78%；归母净利润34.32亿元，同比增长48.67%；归母扣非净利润34.90亿元，同比增长92.94%，环比增长50.69%。值得注意的是，半年报中指出，恒瑞医药已将收到的Merck Healthcare 1.6 亿欧元（...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221915529f47c95f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>确认对外授权一次性收入，恒瑞医药上半年业绩大幅增长</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n确认对外授权一次性收入，恒瑞医药上半年业绩大幅增长\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-22 19:15 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221915529f47c95f&s=b><strong>蓝鲸财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>蓝鲸新闻8月22日讯（记者 屠俊）8月21日晚，江苏恒瑞医药股份有限公司（恒瑞医药，600276.SH）发布2024年半年报，上半年营业收入136.01亿元，同比增长21.78%；归母净利润34.32亿元，同比增长48.67%；归母扣非净利润34.90亿元，同比增长92.94%，环比增长50.69%。值得注意的是，半年报中指出，恒瑞医药已将收到的Merck Healthcare 1.6 亿欧元（...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221915529f47c95f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221915529f47c95f&s=b","article_id":"2461909653","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408221915529f47c95f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2461909653","pubTimestamp":1724325333,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"不过，以此推算，扣除了这笔首付款后，恒瑞医药上半年销售收入同比增速约为10%。有业内人士认为，对外授权为一次性收入，以此对恒瑞医药此次业绩增长的持续性产生质疑。恒瑞医药近年来一直在做创新转型，报告期内，其创新药收入66.12亿元，对外许可收入1.6亿欧元，经估算，两项创新收入总和占总营收比重已过半。仿制药方面，还在拖累恒瑞医药业绩表现，报告期内该公司仿制药收入仍略有下滑。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","BK0196":"行业龙头","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0239":"医药制造","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK0060":"抗癌","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0028":"国家队","BK0188":"融资融券","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK0183":"MSCI概念","BK0012":"证金概念"},"translate_title":"Confirmation of one-time revenue from external authorization, Hengrui Medicine's performance in the first half of the year increased significantly","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1},"content_text":"蓝鲸新闻8月22日讯（记者 屠俊）8月21日晚，江苏恒瑞医药股份有限公司（恒瑞医药，600276.SH）发布2024年半年报，上半年营业收入136.01亿元，同比增长21.78%；归母净利润34.32亿元，同比增长48.67%；归母扣非净利润34.90亿元，同比增长92.94%，环比增长50.69%。值得注意的是，半年报中指出，恒瑞医药已将收到的Merck Healthcare 1.6 亿欧元（按照目前汇率约12.7亿人民币）对外许可首付款确认为收入，利润增加较多。不过，以此推算，扣除了这笔首付款后，恒瑞医药上半年销售收入同比增速约为10%。有业内人士认为，对外授权为一次性收入，以此对恒瑞医药此次业绩增长的持续性产生质疑。恒瑞医药近年来一直在做创新转型，报告期内，其创新药收入（含税，不含对外许可收入）66.12亿元，对外许可收入1.6亿欧元，经估算，两项创新收入总和占总营收比重已过半。创新药收入同比增长33%。其中瑞维鲁胺、达尔西利、恒格列净等产品进入医保后收入快速增长；阿得贝利单抗被多地纳入“惠民保”特药报销目录，收入贡献进一步扩大；海曲泊帕获得多项临床指南推荐，销售收入持续稳定增长；卡瑞利珠单抗、吡咯替尼及阿帕替尼等上市较早的创新药，随着新适应症不断获批及上市后研究积累的翔实循证医学证据，亦有一定的销售增量贡献。不过随着其创新转型，研发费用也在增长，2024年上半年累计研发投入38.60亿元，同比增长26.23%，至今公司累计研发投入超400亿元，其中费用化研发投入 30.38 亿元。仿制药方面，还在拖累恒瑞医药业绩表现，报告期内该公司仿制药收入仍略有下滑。仿制药集采对销售仍然造成一定程度的压力，公告中指出，2024 年 3 月开始执行的第九批国家集采涉及产品注射用醋酸卡泊芬净报告期内销售额同比减少 2.79 亿元；地方集采涉及的产品中，碘佛醇注射液、吸入用七氟烷及盐酸罂粟碱注射液报告期内销售额同比减少 2.76 亿元。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2461909653"}